Target price

Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00

Retrieved on: 
Tuesday, April 9, 2024
Buy, EUR, Target price, BCI, Target, Research, Euronext, ARC, Movement, SCI

EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share.

Key Points: 
  • EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share.
  • This is a premium of 140% to the closing price of EUR 5.00 on April 8, 2024.
  • The initiation report was published April 8, 2024.
  • Stifel joins four other banks whose analysts cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial premiums to the current share price.

MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Research report, Patient, Target price, Target, MET, Survival, Cancer, Kepler Cheuvreux, Fine chemical

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont.
  • With a research report named “Echec et MaaT”, Gilbert Dupont / Groupe Société Générale initiated coverage of MaaT Pharma on April 4th, 2024 with a Buy recommendation and a Target Price of 16 Euros.
  • This new coverage strengthens the visibility of MaaT Pharma among French and international institutional investors and adds to the ongoing coverage by the brokerage firms, Kepler Cheuvreux, KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas.

KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share

Retrieved on: 
Friday, February 9, 2024
KBC, Target, Target price, Buy, Euronext, BCI, Movement, EUR, SCI, ARC, Research, Cryptocurrency

EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that KBC Securities, part of the KBC Group -- a leading Belgian integrated bank-insurance group -- has initiated research coverage of ONWARD Medical with a Buy rating and Target Price of EUR 10.00 per share.

Key Points: 
  • EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that KBC Securities, part of the KBC Group -- a leading Belgian integrated bank-insurance group -- has initiated research coverage of ONWARD Medical with a Buy rating and Target Price of EUR 10.00 per share.
  • This is a premium of 161% to the closing price of EUR 3.83 on February 8, 2024.
  • KBC joins three other banks whose research analysts cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial premiums to the current share price.
  • “KBC Securities’ initiation of coverage reflects strong confidence in our ability to achieve this year’s milestones, which include the planned commercialization of our ARC-EX® platform later this year,” said Dave Marver, CEO of ONWARD Medical.

Vendavo to Outline Criticality of Target Price Guidance During Sept 22 Webinar with Professional Pricing Society

Retrieved on: 
Thursday, September 10, 2020
Competition, Pricing, Target costing, Target price, Economics

DENVER, Sept. 10, 2020 /PRNewswire-PRWeb/ --To help organizations gain more credibility and win more deals profitably, Vendavo , a market leader in commercial excellence solutions, will host a webinar, How Target Price Guidance is Key for Turbulent Times with the Professional Pricing Society (PPS) on Tuesday, September 22 at 9am PT | 12pmET | 6pm CET.

Key Points: 
  • DENVER, Sept. 10, 2020 /PRNewswire-PRWeb/ --To help organizations gain more credibility and win more deals profitably, Vendavo , a market leader in commercial excellence solutions, will host a webinar, How Target Price Guidance is Key for Turbulent Times with the Professional Pricing Society (PPS) on Tuesday, September 22 at 9am PT | 12pmET | 6pm CET.
  • Led by David Anderson, Business Consultant, Vendavo, participants will learn about how to proactively set strategies for managing the ways customers consider price.
  • Why target price guidance is now more needed than ever.
  • What type of guidance target pricing should include.